^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HS627 (pertuzumab biosimilar)
i
Other names: HS627
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Zhejiang Hisun
Drug class:
HER2 dimerization inhibitor
Related drugs:
13d
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (clinicaltrials.gov)
P3, N=408, Active, not recruiting, BioRay Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Nov 2021 --> Dec 2025
Enrollment closed • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • HS627 (pertuzumab biosimilar)
over5years
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (clinicaltrials.gov)
P3, N=408, Recruiting, Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Clinical • New P3 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • HS627 (pertuzumab biosimilar)
Share via
